Sign in
4

Changes in Ownership

UNITED THERAPEUTICS Corp Filed Acc 0001673232-25-000017

PRESIDENT AND COO sold 22,500 shares at an average $514.35 ($11,572,963)

  • PRESIDENT AND COO acquired 14,625 shares (option exercise)
  • PRESIDENT AND COO acquired 7,875 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

BENKOWITZ MICHAEL · PRESIDENT AND COO

Table I: Non-derivative

17 lines
Date Transaction Shares Price Value Owned after D/I
2025-12-22 Exercise or conversion : show line 1 in the form 10b5-1 −14,625 $117.76 $1,722,240 14,625 I
2025-12-22 Sale : show line 2 in the form 10b5-1 −682 $512.14 $349,278 13,943 I
2025-12-22 Sale : show line 3 in the form 10b5-1 −848 $513.40 $435,363 13,095 I
2025-12-22 Sale : show line 4 in the form 10b5-1 −11,815 $514.31 $6,076,534 1,280 I
2025-12-22 Sale : show line 5 in the form 10b5-1 −440 $515.53 $226,834 840 I
2025-12-22 Sale : show line 6 in the form 10b5-1 −560 $516.37 $289,166 280 I
2025-12-22 Sale : show line 7 in the form 10b5-1 −200 $517.74 $103,548 80 I
2025-12-22 Sale : show line 8 in the form 10b5-1 −80 $518.91 $41,513 0 I
Open-market sales · 22,500 sh · avg $514.35 · $11,572,963

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2025-12-22 Exercise or conversion : show line 18 in the form 10b5-1 Stock Options −6,190 0 I
2025-12-22 Exercise or conversion : show line 19 in the form 10b5-1 Stock Options −1,685 68,065 I
2025-12-22 Exercise or conversion : show line 20 in the form 10b5-1 Stock Options −14,625 126,375 I
Loading xslF345X05/primarydocument.xml…